ArticleDiscover oncology2025
Gross total resection in low-grade and pretreated high-grade invasive growth hormone pituitary adenomas promises favorable outcomes.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionGrowth hormone (GH)-secreting pituitary tumors cause serious systemic comorbidities, necessitating the achievement of gross total resection (GTR) and biochemical remission. This study aims to identify predictors of resection status and biochemical remission.
methodsWe retrospectively reviewed the records of 54 GH adenoma patients receiving endoscopic endonasal transsphenoidal approach (EETSA). Medical records and magnetic resonance imaging were reviewed for tumor size, volume, resection status, invasion status, and Knosp and Hardy-Wilson grades. We also classified invasion status into high- and low-grade groups. Biochemical remission was defined as an insulin-like growth factor 1 value within sex- and age-adjusted reference or a random GH level < 1.0 ng/mL.
resultsThe degrees of horizontal and vertical invasion based on preoperative Knosp and Hardy-Wilson grade were highly associated with intraoperative resection status (p = 0.0054, 0.0043 and 0.013 respectively). We also found more significant differences between resection status and higher-grade invasion (p = 0.0018, 0.006 and 0.0018, respectively). Hardy-Wilson grades and resection status were significantly associated with biochemical remission (p = 0.0484, 0.0252, and 0.0007, respectively). Although we observed no difference between outcomes with respect to micro- vs. macroadenoma, tumor size and volume were significantly associated with outcomes (p = 0.017, 0.0032, respectively). More significant differences were observed between biochemical remission and higher-grade Hardy-Wilson invasion grade (p = 0.0053 and 0.0075). Multivariate analysis showed that higher-grade Hardy-Wilson invasion correlated with resection status (p = 0.0481 and 0.0125); only resection status was associated with biochemical remission (p = 0.0101).
conclusionsEETSA remains the best treatment option for GH adenomas. Biochemical remission was highly associated with invasion status and the possibility of achieving GTR. Aggressive resection for low-grade and pretreated high-grade tumors promises favorable outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.